The Impact of Smoking Cessation on Hospitalization and Psychiatric Medication Utilization among People with Serious Mental Illness

被引:3
作者
Kertes, Jennifer [1 ]
Reisner, Orit Stein [2 ]
Grunhaus, Leon [3 ]
Neumark, Yehuda [4 ,5 ]
机构
[1] Maccabi HealthCare, Dept Hlth Evaluat & Res, Jerusalem, Israel
[2] Maccabi HealthCare Serv, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Braun Hebrew Univ, Hadassah Sch Publ Hlth & Community Med, Jerusalem, Israel
[5] Hebrew Univ Jerusalem, Hadassah Braun Sch Publ Hlth & Community Med, POB 12272, IL-9112102 Jerusalem, Israel
关键词
Smoking cessation; serious mental illness; hospitalization; medication utilization; defined daily dose; psychotropic medications; BIPOLAR DISORDER; LIFE EXPECTANCY; SCHIZOPHRENIA; MORTALITY; SMOKERS; PREDICTORS; EFFICACY; SAFETY; IMPLEMENTATION; ASSOCIATION;
D O I
10.1080/10826084.2021.1942057
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Despite the high prevalence of smoking amongst people with serious mental illness (SMI), referral rates to smoking cessation programs (SCPs) are low. Mental health workers reticence to refer to SCPs has been attributed, in part, to their belief that quitting will have a deleterious effect on their patients' mental health status. Objectives: This study's objective was to determine if participating in a smoking cessation program had an adverse effect on mental health status among people with SMI, measured here by a change in hospitalization occurrence or psychiatric medication utilization. People with SMI who had participated in at least one SCP session in a large health maintenance organization (n = 403) were compared to an age-gender-diagnosis matched sample of SMI smokers (1,209) who had never participated. Results: No change in psychiatric hospitalization occurrence pre- versus post-SCP participation was found among participants (Pre:7.2% vs. Post:5.2, p = 0.2) or nonparticipants (Pre:7.0% vs. Post:6.0%, p = 0.2). Mean defined daily dose (DDD) for anti-psychotic, mood stabilizer, anti-depressant and anxiolytic medications also did not change over time for participants and nonparticipants. However, participants who did not complete the SCP and didn't quit had a 0.35 higher mean DDD for anti-psychotic medications compared with participants who had completed the SCP or quit, and with nonparticipants (p = 0.006), and were the only group to exhibit an increase in mean antipsychotic DDD over time (Pre:1.42, Post:1.63). SCP participation was not associated with hospitalization occurrence or psychiatric medication utilization. Conclusions/Importance: Smoking cessation should be encouraged, with close monitoring during the quit process.
引用
收藏
页码:1543 / 1550
页数:8
相关论文
共 41 条
[1]   Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial [J].
Anthenelli, Robert M. ;
Benowitz, Neal L. ;
West, Robert ;
St Aubin, Lisa ;
McRae, Thomas ;
Lawrence, David ;
Ascher, John ;
Russ, Cristina ;
Krishen, Alok ;
Evins, A. Eden .
LANCET, 2016, 387 (10037) :2507-2520
[2]  
APA Workgroup on Tobacco Use Disorder Council on Addiction Psychiatry, 2015, POS STAT TOB US DIS
[3]   A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder [J].
Baker, Amanda ;
Richmond, Robyn ;
Haile, Melanie ;
Lewin, Terry J. ;
Carr, Vaughan J. ;
Taylor, Rachel L. ;
Jansons, Sylvia ;
Wilhelm, Kay .
AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (11) :1934-1942
[4]   Depressive mood, suicide ideation and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit day [J].
Berlin, Ivan ;
Chen, Henian ;
Covey, Lirio S. .
ADDICTION, 2010, 105 (12) :2209-2216
[5]   Nicotine withdrawal in smokers with current depressive disorders undergoing intensive smoking cessation treatment [J].
Blalock, Janice A. ;
Robinson, Jason D. ;
Wetter, David W. ;
Schreindorfer, Lisa S. ;
Cinciripini, Paul M. .
PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2008, 22 (01) :122-128
[6]   Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia [J].
Bloch, Boaz ;
Reshef, Alon ;
Cohen, Tamara ;
Tafla, Amos ;
Gathas, Samich ;
Israel, Salomon ;
Gritsenko, Inga ;
Kremer, Ilana ;
Ebstein, Richard P. .
PSYCHIATRY RESEARCH, 2010, 175 (1-2) :38-42
[7]   Factors Influencing Implementation of Smoking Cessation Treatment Within Community Mental Health Centers [J].
Brown, Clayton H. ;
Medoff, Deborah ;
Dickerson, Faith B. ;
Fang, Li Juan ;
Lucksted, Alicia ;
Goldberg, Richard W. ;
Kreyenbuhl, Julie ;
Himelhoch, Seth ;
Dixon, Lisa B. .
JOURNAL OF DUAL DIAGNOSIS, 2015, 11 (02) :145-150
[8]   Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations [J].
Cather, Corinne ;
Pachas, Gladys N. ;
Cieslak, Kristina M. ;
Evins, A. Eden .
CNS DRUGS, 2017, 31 (06) :471-481
[9]   Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London [J].
Chang, Chin-Kuo ;
Hayes, Richard D. ;
Perera, Gayan ;
Broadbent, Mathew T. M. ;
Fernandes, Andrea C. ;
Lee, William E. ;
Hotopf, Mathew ;
Stewart, Robert .
PLOS ONE, 2011, 6 (05)
[10]   Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) [J].
De Hert, M. ;
Dekker, J. M. ;
Wood, D. ;
Kahl, K. G. ;
Holt, R. I. G. ;
Moeller, H. -J. .
EUROPEAN PSYCHIATRY, 2009, 24 (06) :412-424